At the BioNJ BioPartnering Conference in New Jersey, global biopharma innovators, investors, and business development executives gathered to ignite the next wave of life science growth. With macroeconomic shifts placing an intense premium on capital efficiency, Intelligencia AI was on-site collaborating with regional ecosystem leaders to demonstrate how purpose-built machine learning removes legacy blind spots from asset valuation. By delivering objective, scientific data on a drug’s true probability of technical and regulatory success (PTRS), our predictive analytics platform empowers cross-functional teams to eliminate guesswork from due diligence, optimize funding pipelines, and confidently secure high-value partnerships.
